Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances

Roche (RHHBY) posted nine-month 2026 sales of CHF 46.5 billion, up 6% at constant exchange rates, and held its full-year outlook of mid-single-day growth steady. The Pharmaceuticals division led, growing 7%.

Five key drugs generated CHF 16.8 billion in sales, up 12% at CER. That growth absorbed declines in legacy products hit by loss of exclusivity, a sign that the newer franchises are carrying the top line.

Management reaffirmed mid-single-digit sales growth guidance for 2026 and expects high-single-digit EPS growth. Holding guidance after nine months suggests the company sees no need to lift or cut its targets.

The pipeline offers the speculative angle. Roche cited candidates in oncology, immunology, and obesity. Enicepatide delivered encouraging phase II results in type 2 diabetes and weight management. That places Roche in the obesity conversation alongside LLY and NVO, though a phase II readout is early-stage evidence, and any competitive read-through is interpretation rather than a stated outcome. NRIX, also tied to this theme by the classifier, has no figures in the source.